Idex Corp. reports Q4 EPS $1.83, consensus $1.78

Reports Q4 revenue $788.9M, consensus $769.1M. “IDEX businesses weathered an unprecedented year of global recalibration, which played out differently across our segments. Our team’s agility and core execution capabilities, combined with the quality of our underlying assets, enabled us to deliver strong results in a challenging environment,” said Eric D. Ashleman, CEO. “Now, the majority of our end markets are stable, supporting the early stages of focused organic growth to drive our next chapter of outperformance. However, the timing of market recovery within our Life Sciences and Analytical Instrumentation businesses remains uncertain, moderating our overall full year growth outlook. We continue to aggressively pursue inorganic opportunities within advantaged, fast-growing markets, as demonstrated by our purchase of STC Material Solutions in December. Our funnel of potential acquisitions is strong and our efforts are well supported by ample capacity on our balance sheet.”